In xenografts of HNSCC cells, a combination of HON with erlotinib [38] and HON with cetuximab (monoclonal antibody against the extracellular domain of EGFR) [29] caused a more significant reduction in tumor volume in comparison to those chemicals used individually. Here, EGFR is linked to head and neck squamous cell carcinoma.